David Waltz

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>

Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey et al. · New England Journal of Medicine · 2015 · 1.6K citations · Full text

Identification of the urokinase receptor as an adhesion receptor for vitronectin.

Ying Wei, David Waltz, Navin Rao et al. · Journal of Biological Chemistry · 1994 · 586 citations · Full text

Cell Adhesion, Urokinase Receptor Expression, Immunology +20

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Michael Boyle, Scott C. Bell, Michael W. Konstan et al. · The Lancet Respiratory Medicine · 2014 · 436 citations

Pathology, Cftr Corrector, Pulmonary Fibrosis +3

Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis

Richard B. Moss, David M. Rodman, L. Terry Spencer et al. · CHEST Journal · 2004 · 383 citations

Pathogenesis, Pathology, Respiratory Infection +4

Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis

Ronald L. Gibson, Julia Emerson, Sharon McNamara et al. · American Journal of Respiratory and Critical Care Medicine · 2003 · 314 citations

Antibiotics, Inhaled Tobramycin, Pediatrics +8